Skip to main navigation Skip to search Skip to main content

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Domenica Lorusso*, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel FabbroBarbara Schmalfeldt, Dominique Berton, Antje Belau, Jean-Pierre Lotz, Martina Gropp-Meier, Laurence Gladieff, Hans-Joachim Lück, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Isabelle Ray-Coquard

*Corresponding author for this work
57 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology